Patents by Inventor Mark E. Samuels

Mark E. Samuels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Federation policy exchange
    Patent number: 11979744
    Abstract: Federation policy exchange is provided in response to receiving a sharing query from an Access Point (AP) indicating that an associated wireless network supports federated identities with data sharing, determining whether the sharing query is within sharing preferences; and in response to determining that the sharing query is within the sharing preferences, transmitting, to the AP, a positive response for identity sharing that authorizes collection and sharing of identity data with at least one entity identified in a sharing policy for the associated wireless network. In various embodiments, federation policy exchange includes transmitting a support notification, via an AP, indicating support for federated identities with data sharing within a wireless network associated with the AP; and in response to receiving a first identify sharing preference from a User Equipment (UE) that indicates that negotiation is preferred, transmitting a sharing policy for the wireless network to the UE.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: May 7, 2024
    Assignee: Cisco Technology, Inc.
    Inventors: Jerome Henry, Louis G. Samuel, Mark Grayson, Bart A. Brinckman, Robert E. Barton, Carlos M. Pignataro, Nagendra Kumar Nainar, Matthew MacPherson
  • Methods for identifying analgesic agents
    Patent number: 9086420
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: July 21, 2015
    Assignee: Xenox Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for treating pain by inhibition of the SCN9A channel
    Patent number: 8410054
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: April 2, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20110306654
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: May 27, 2011
    Publication date: December 15, 2011
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20100323359
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: April 26, 2010
    Publication date: December 23, 2010
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Publication number: 20100076058
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Marcia I. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • Methods for identifying analgesic agents
    Patent number: 7659082
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: February 9, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg